Aska Pharmaceutical Reports Interim Operating Profit Growth
Aska Pharmaceutical Holdings reported consolidated operating profit growth of 3.5% for the September interim period and forecasts 6.3% growth for the fiscal year ending in March.
Related stories
StubHub Raises Full-Year Gross Merchandise Sales Outlook to $10.3 Billion
StubHub raised its full-year gross merchandise sales outlook to $10.3 billion from $10.1 billion.
M impact | EARNINGS | Nov 15, 2026, 02:03 AM UTC
Merlin Properties Raises 2026 FFO Guidance to EUR 0.58 per Share
Merlin Properties raised its 2026 FFO guidance to EUR 0.58 per share and updated its strategy for its 704 MW data center portfolio.
M impact | EARNINGS | Nov 14, 2026, 08:03 PM UTC
Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million
Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million Lucara Diamond raised
L impact | EARNINGS | Nov 14, 2026, 01:10 AM UTC
Gilead Expects HIV Revenue to Grow About 12% in 2026
Gilead expects HIV revenue to grow about 12% in fiscal 2026.
M impact | EARNINGS | Nov 14, 2026, 12:44 AM UTC
Asante Gold Withdraws 2026 Production and Cost Guidance
Asante withdrew its 2026 guidance for 275,000–300,000 equivalent ounces at consolidated AISC of $3,200–$3,600/oz after Bibiani underperformed. Nine-month production was 165,594 equ
M impact | EARNINGS | Nov 13, 2026, 11:27 PM UTC
Japan's FiEE 9M Revenue More Than Quadruples
FiEE's nine-month revenue more than quadrupled, attributed to SaaS expansion.
M impact | EARNINGS | Nov 13, 2026, 10:28 PM UTC